BRPI0820387A2 - Agentes de ligação de wise e epítopos - Google Patents

Agentes de ligação de wise e epítopos

Info

Publication number
BRPI0820387A2
BRPI0820387A2 BRPI0820387-3A BRPI0820387A BRPI0820387A2 BR PI0820387 A2 BRPI0820387 A2 BR PI0820387A2 BR PI0820387 A BRPI0820387 A BR PI0820387A BR PI0820387 A2 BRPI0820387 A2 BR PI0820387A2
Authority
BR
Brazil
Prior art keywords
epitopes
binding agents
wise binding
wise
agents
Prior art date
Application number
BRPI0820387-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Xueming Qian
Kevin Graham
Grant Shimamoto
Barbara S Tipton
Mei-Mei Tsai
Aaron George Winters
Li Zhang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BRPI0820387A2 publication Critical patent/BRPI0820387A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0820387-3A 2007-11-21 2008-11-21 Agentes de ligação de wise e epítopos BRPI0820387A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US403707P 2007-11-21 2007-11-21
PCT/US2008/012987 WO2009070243A2 (en) 2007-11-21 2008-11-21 Wise binding agents and epitopes

Publications (1)

Publication Number Publication Date
BRPI0820387A2 true BRPI0820387A2 (pt) 2015-05-26

Family

ID=40524859

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820387-3A BRPI0820387A2 (pt) 2007-11-21 2008-11-21 Agentes de ligação de wise e epítopos

Country Status (17)

Country Link
US (2) US8043620B2 (cg-RX-API-DMAC7.html)
EP (1) EP2220118A2 (cg-RX-API-DMAC7.html)
JP (2) JP5583591B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100099193A (cg-RX-API-DMAC7.html)
CN (1) CN101925611A (cg-RX-API-DMAC7.html)
AU (1) AU2008330125B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0820387A2 (cg-RX-API-DMAC7.html)
CA (1) CA2705879A1 (cg-RX-API-DMAC7.html)
CO (1) CO6311002A2 (cg-RX-API-DMAC7.html)
CR (1) CR11523A (cg-RX-API-DMAC7.html)
EA (1) EA201000844A1 (cg-RX-API-DMAC7.html)
IL (1) IL205569A0 (cg-RX-API-DMAC7.html)
MA (1) MA31918B1 (cg-RX-API-DMAC7.html)
MX (1) MX2010005656A (cg-RX-API-DMAC7.html)
TN (1) TN2010000213A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009070243A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201003578B (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005266875B2 (en) 2004-07-23 2012-07-26 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
CN105001320A (zh) 2005-11-23 2015-10-28 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN101835485B (zh) 2007-02-01 2016-10-26 阿塞勒隆制药公司 活化素-actriia拮抗剂及在治疗或预防乳腺癌中的用途
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
JP5574711B2 (ja) 2007-02-09 2014-08-20 アクセルロン ファーマ， インコーポレイテッド 癌患者における骨成長を促進するためのアクチビン−ａｃｔｒｉｉａアンタゴニストおよびその使用
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010019261A1 (en) 2008-08-14 2010-02-18 Acceleron Pharma Inc. Use of gdf traps to increase red blood cell levels
WO2011063127A1 (en) 2009-11-18 2011-05-26 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
EP2387412A4 (en) 2009-01-13 2013-04-03 Acceleron Pharma Inc PROCESS FOR INCREASING THE ADIPONECTIN MIRROR
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
BRPI1010704B1 (pt) 2009-06-12 2021-12-14 Acceleron Pharma Inc Polipeptídeo recombinante, proteína de fusão recombinante, preparação farmacêutica e uso da mesma
WO2011025964A2 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
US9849192B2 (en) 2009-11-18 2017-12-26 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
EP2507381A4 (en) * 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
WO2011075636A2 (en) 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
BR112012021941A2 (pt) * 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
AU2012327223A1 (en) 2011-11-30 2013-06-20 Wellstat Diagnostics, Llc. Assays, antibodies, immunogens and compositions related to 5-FU
WO2013103800A1 (en) * 2012-01-06 2013-07-11 Bioalliance C.V. Anti-transferrin receptor antibodies and methods using same
FR2987293B1 (fr) * 2012-02-27 2014-03-07 Michelin & Cie Procede et appareil pour realiser des objets tridimensionnels a proprietes ameliorees
EP2904015A4 (en) 2012-10-02 2016-10-05 Univ Rutgers TARGETED RELEASE OF ANTIBODIES TO ACTIVATED MATRIPTASE-CONJUGATED TOXINS
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
BR112015010360A8 (pt) 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
US20140171356A1 (en) * 2012-12-12 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Chemically immobilized wnt protein and methods of use
AU2014315081A1 (en) 2013-09-05 2016-03-24 Duke University Nav1.7 antibodies and methods of using the same
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
AP2017009674A0 (en) 2014-06-13 2017-01-31 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
UA122673C2 (uk) 2014-11-07 2020-12-28 Елевен Байотерапьютікс, Інк. Антитіло, що специфічно зв'язується з людським il-6
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
JP2019510078A (ja) 2016-02-23 2019-04-11 セセン バイオ， インコーポレイテッド Ｉｌ−６アンタゴニスト製剤およびその使用
CA3017958C (en) 2016-03-18 2024-03-12 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties
EP3448875A4 (en) * 2016-04-29 2020-04-08 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018129248A1 (en) * 2017-01-06 2018-07-12 The Regents Of The University Of California Therapeutic anti-ige antibodies and methods and compositions thereof
US11021540B2 (en) * 2017-09-07 2021-06-01 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
KR20220034176A (ko) * 2019-07-12 2022-03-17 고쿠리츠 다이가쿠 호진 교토 다이가쿠 치아의 재생 치료를 위한 usag-1을 표적 분자로 한 중화 항체
CN112180099B (zh) * 2020-09-15 2022-07-29 江南大学附属医院 子宫内膜异位症血清标志物的应用
IL314524A (en) 2022-01-28 2024-09-01 Georgiamune Inc Antibodies to programmed cell death protein 1 that are agonists for PD-1
CN115322258B (zh) * 2022-05-31 2024-08-13 武汉真福医药股份有限公司 一种单克隆抗体qkma-1g41及其应用
CN115304677B (zh) * 2022-06-19 2024-08-16 湖北真福医药有限公司 一种抗枯草芽孢杆菌纤溶酶的单克隆抗体qkma-9a10及应用
CN116712533B (zh) * 2023-07-03 2024-02-02 广东暨安特博生物科技有限公司 一种sostdc1蛋白在制备治疗皮肤病产品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2220912A1 (en) * 1995-06-05 1996-12-12 Gregg A. Hastings Human ccn-like growth factor
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2003276430A1 (en) * 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
MXPA06010887A (es) * 2004-03-23 2007-03-08 Amgen Inc Anticuerpos monoclonales especificos para ox4ol (cd 134l) humano.
PL3345607T3 (pl) * 2006-12-29 2023-01-09 Ossifi-Mab Llc Sposoby modyfikowania wzrostu kości poprzez podanie antagonisty lub agonisty sost lub wise
WO2008156712A1 (en) * 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2010131185A1 (en) * 2009-05-12 2010-11-18 Pfizer Inc. Blocking anti-dkk-1 antibodies and their uses

Also Published As

Publication number Publication date
WO2009070243A3 (en) 2009-10-29
ZA201003578B (en) 2011-04-28
CA2705879A1 (en) 2009-06-04
IL205569A0 (en) 2010-12-30
TN2010000213A1 (en) 2011-11-11
WO2009070243A2 (en) 2009-06-04
JP2011504501A (ja) 2011-02-10
MA31918B1 (fr) 2010-12-01
JP2014167002A (ja) 2014-09-11
CN101925611A (zh) 2010-12-22
EA201000844A1 (ru) 2011-10-31
MX2010005656A (es) 2010-11-12
US20090130114A1 (en) 2009-05-21
US20120003237A1 (en) 2012-01-05
AU2008330125B2 (en) 2012-11-22
US8043620B2 (en) 2011-10-25
US8309092B2 (en) 2012-11-13
JP5583591B2 (ja) 2014-09-03
KR20100099193A (ko) 2010-09-10
CO6311002A2 (es) 2011-08-22
EP2220118A2 (en) 2010-08-25
AU2008330125A1 (en) 2009-06-04
CR11523A (es) 2010-12-16

Similar Documents

Publication Publication Date Title
BRPI0820387A2 (pt) Agentes de ligação de wise e epítopos
CY2020009I2 (el) Δεσμευτικοι παραγοντες σκληροστινης
PT2173888T (pt) Resumo
ATE543405T1 (de) Frisiergerät
ATE443753T1 (de) Nuancierungsmittel
DK2178568T3 (da) Kontrastmidler
BRPI0807137A2 (pt) Agentes antiparasitários
EP3241842C0 (en) PRESENTATION OF LIAISON AGENTS
EP2155121A4 (en) INTERSPINED DISTANCE MEMBER
DE602006021235D1 (de) Kristallglasgegenstand
EP2215246A4 (en) PROTEIN SCAFFOLDS
HRP20170963T1 (hr) Modificirani saharidi
BRPI0806964A2 (pt) Combinações de agonístico beta-2-adrenoceptor e benzotiazolona
EP2117452A4 (en) TROCHANTARY HANDLE
BRPI0915367A2 (pt) peptídeos e epítopos anti-p2x7
FI7098U1 (fi) Kaidejärjestelmä
BRPI0818697A2 (pt) Depilador
EP2214719A4 (en) Metallofullerene-DYE
EP2197447A4 (en) ANTIFUNGALS
EP2217071A4 (en) ANTIMYCOTIC AGENTS
BRPI0807603A2 (pt) Composição depilatóra
EP2202304A4 (en) MODIFIED CREATININE AMIDOHYDROLASE
FI20050547A0 (fi) Side
FR2901185B1 (fr) Ouvrant arriere renforce
FI20070466A0 (fi) Sidontalaite

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.